Get started
Author

Baisong Mei

Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
2015 · Jennifer Dumont, Don Euwart, et al. · Critical Reviews in Biotechnology · 483
PDF
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
2010 · Baisong Mei, Clark Pan, et al. · Blood · 229
PDF
Lysophosphatidic Acid and Sphingosine 1-Phosphate Protection of T Cells from Apoptosis in Association with Suppression of Bax
1999 · Edward J Goetzl, Yvonne Kong, et al. · The Journal of Immunology · 212
PDF
Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats
2004 · Christopher J. Parsons, Blair U. Bradford, et al. · Hepatology · 193
PDF
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
2023 · Guy Young, Alok Srivastava, et al. · The Lancet · 139
BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice
2020 · Ekta Seth Chhabra, Tongyao Liu, et al. · Blood · 123
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort
2021 · K. John Pasi, Toshko Lissitchkov, et al. · Journal of Thrombosis and Haemostasis · 109
PDF
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
2023 · Alok Srivastava, Savita Rangarajan, et al. · The Lancet Haematology · 108
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
2024 · Gili Kenet, Beatrice Nolan, et al. · Blood · 49
PDF
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein
2015 · Justin McCue, Rashmi Kshirsagar, et al. · Biologicals · 48
PDF
Changes in health‐related quality of life with treatment of longer‐acting clotting factors: results in the A‐ LONG and B‐ LONG clinical studies
2016 · K. W. Wyrwich, S. Krishnan, et al. · Haemophilia · 45
Versatile Expression System for Rapid and Stable Production of Recombinant Proteins
2003 · M.‐S. Cho, H. Yee, et al. · Biotechnology Progress · 44
Expression of Human Coagulation Factor VIII in a Human Hybrid Cell Line, HKB11
2006 · Baisong Mei, Yaoqi Chen, et al. · Molecular Biotechnology · 38
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B
2016 · K.John Pasi, Kathelijn Fischer, et al. · Thrombosis and Haemostasis · 34
Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates
2014 · Jerry Powell, Amy Shapiro, et al. · British Journal of Haematology · 34
PDF
Validation of the manufacturing process used to produce long‐acting recombinant factor IX Fc fusion protein
2014 · J. McCue, D. Osborne, et al. · Haemophilia · 32
PDF
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease
2026 · Rabi Hanna, Haydar Frangoul, et al. · New England Journal of Medicine · 27
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia
2026 · Haydar Frangoul, Rabi Hanna, et al. · New England Journal of Medicine · 23
AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
2023 · Rabi Hanna, Haydar Frangoul, et al. · Blood · 19
Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)
2021 · Alok Srivastava, Savita Rangarajan, et al. · Blood · 18
Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)
2021 · Guy Young, Alok Srivastava, et al. · Blood · 16
Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events
2019 · Steven Pipe, Margaret V. Ragni, et al. · Blood · 13
A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity
2014 · Yang Buyue, Tongyao Liu, et al. · PLoS ONE · 12
PDF
Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study
2020 · Steven W. Pipe, John Pasi, et al. · Blood · 10
Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial
2024 · Rabi Hanna, Haydar Frangoul, et al. · Blood · 8
Works count: 53
Citation count: 2,131
H-index: 19
I10-index: 24
Year
Topic
Type